Beta Cell Cluster Reaggregation for Functional Islet Transplants
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The shortage of pancreatic islets donors hinders the effective implementation of pancreatic islet transplantation for treating diabetes, and existing artificial pancreas alternatives do not adequately address the need for functional islet grafts.
Innovation Solution
A composition comprising dissociated insulin-positive endocrine progenitor cells, combined with specific inhibitors and modulators such as BMP signaling pathway inhibitors, ROCK inhibitors, and histone methyltransferase inhibitors, which enhance the reaggregation of cells into functional beta cell clusters with improved viability and glucose-stimulated insulin secretion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pancreatic islet transplantation is performed to treat diabetes, then functional insulin secretion is restored, but donor availability is severely limited
Solution Approach 1:
The patent creates artificial beta cell clusters that copy the functional properties of natural pancreatic beta cells. These synthetic clusters are generated from pluripotent stem cells or pancreatic progenitor cells, replicating the insulin secretion capability without requiring donor pancreases. The clusters are engineered to respond to glucose stimulation by secreting insulin, mimicking the physiological function of native beta cells.
Solution Approach 2:
The patent uses an intermediary approach by generating beta cell clusters in vitro from stem cells or progenitor cells, then transplanting these cultured clusters directly into the recipient. This intermediary culture step allows expansion and functional maturation of beta cells before transplantation, bridging the gap between limited donors and high patient demand.
2Quantity of substance
If artificial pancreas alternatives are used to address donor shortage, then transplantable islet supply increases, but functional equivalence to natural islets is insufficient
Solution Approach 1:
The patent employs parameter changes by controlling culture conditions, growth factors, and signaling pathways during the generation of beta cell clusters. By adjusting biochemical parameters such as glucose concentration, growth factor levels, and signaling molecule presence, the clusters achieve functional maturation and insulin secretion capability comparable to natural islets.
Solution Approach 2:
The patent applies preliminary action by pre-differentiating stem cells or progenitor cells into beta cell-like clusters under controlled conditions before transplantation. This preliminary culturing and functional maturation process ensures that the transplanted clusters are already equipped with insulin secretion capability, improving their functional equivalence to natural islets upon implantation.
Data Source
AI summary
Provided herein are methods of manufacturing β cells in vitro. Also provided herein are methods of treating a disease in a subject comprising administering the β cells manufactured in vitro to the subject. Also provided herein are methods of differentiating stem cells into β cells.